ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Samsung BioLogics trading suspended after fraud ruling

South Korean financial regulator orders delisting review

Samsung BioLogics breached accounting rules before its stock exchange listing in 2016, according to South Korea's top financial regulator.

SEOUL -- South Korea's financial regulator suspended share trading of Samsung BioLogics on Wednesday and fined the world's third largest contract drugmaker 8 billion won ($7.05 million), after ruling that it had committed accounting fraud in 2015 to inflate its value ahead of an initial public offering in 2016.

The Securities and Futures Commission also ordered the Korea Exchange, the stock market operator, to review whether Samsung BioLogics should be delisted. This would be a significant blow to the Samsung group, which has bet on the biotech company as a future growth engine to reduce its reliance on the smartphone and semiconductor businesses. The stock market operator is expected to make a final decision in about a month.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more